272BIO
0762.638.249 · rovalta.com · 23/09/2026
272BIO
Overview
What does 272BIO do?
272BIO is a Private limited company incorporated in 2021. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Gent. It employs on average 5,2 ETP workers (FTE).
9052 Gent · FlandreSee on map
Joint committees (1)
- 207
Trend over 4 financial years
| 2025 | 2024 | 2023 | 2022 | ||||
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Gross margin | 104,3 k € | +490% | 17,7 k € | -60.3% | 44,5 k € | +342% | -18,4 k € |
| EBITDA | -530,8 k € | -36.6% | -388,5 k € | -55.5% | -249,9 k € | -262% | -69 k € |
| Operating result | -605,9 k € | -43.7% | -421,7 k € | -61.2% | -261,6 k € | -279% | -69 k € |
| Net result | -631,6 k € | -38.1% | -457,2 k € | -64.3% | -278,3 k € | -296% | -70,2 k € |
| Balance sheet | |||||||
| Equity | -225,3 k € | -155% | 406,3 k € | +221% | -336,5 k € | -478% | -58,2 k € |
| Total assets | 709,6 k € | -55.1% | 1,6 M € | +178% | 569,6 k € | +2616% | 21 k € |
| Cash | 350,8 k € | -69.0% | 1,1 M € | +2413% | 45,1 k € | +229% | 13,7 k € |
| Debts | 855,7 k € | -27.2% | 1,2 M € | +29.6% | 906,2 k € | +1044% | 79,2 k € |
| Other | |||||||
| Workforce | 5,2 ETP | +48.6% | 3,5 ETP | +25.0% | 2,8 ETP | – | |
Board of directors
Seen on filing of 30/06/2025 · 4 active · 1 ended
Active mandates
Ended mandates
Other companies at this address
| Company | CBE no. |
|---|---|
AmphiStar● Active | 0771.868.491 |
Biotope General Partner● Active | 1023.886.864 |
Biotope Ventures● Active | 0786.781.648 |
Biotope Ventures II● Active | 1024.242.497 |
EU-LIFE● Active | 1038.799.823 |
EU-SAGE● Active | 0774.834.218 |
I-CHALLENGE● Active | 1002.343.560 |
LO²CUS Gent● Active | 0642.937.081 |
Obulytix● Active | 0803.351.624 |
ORIONIS BIOSCIENCES● Active | 0635.962.088 |
Rainbow Crops● Active | 1022.560.538 |
S-Biomedic● Active | 0668.407.105 |
Typcal Europe● Active | 1028.922.352 |
VIB BIO-INCUBATOR● Active | 0711.986.235 |
| 0456.343.923 | |
Xpert Protein● Active | 1014.642.467 |
Financials
Full financial information
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/07/2024 | 01/07/2023 | 01/07/2022 | 28/01/2021 |
| Closing of the financial year | 30/06/2025 | 30/06/2024 | 30/06/2023 | 30/06/2022 |
| Length of the financial year | 12 months | 12 months | 12 months | 18 months |
| Filing date | 12/01/2026 | 30/01/2025 | 31/01/2024 | 06/02/2023 |
| General meeting | 15/12/2025 | 16/12/2024 | 25/01/2024 | 15/12/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Looking for more information about this company?
Try for 7 daysAnnual accounts filings
4 filings with the NBB
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Seen on filing of 30/06/2025 · 4 active · 1 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source: Belgian Official Gazette
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-631,6 k €↓
- 2024Annual accounts 2024-457,2 k €↓
- 2023Annual accounts 2023-278,3 k €↓
- 2022Annual accounts 2022-70,2 k €
- 28/01/2021IncorporationPrivate limited company